`How Crazy Is That?': Left Dismisses Ackman's Valeant Defense
- The Citron short says Ackman doesn't know Valeant very well
- Stock continues to fall following the Pershing presentation
Ackman Defends Valeant, Wall Street Unloads Stocks
This article is for subscribers only.
Andrew Left, the short seller who unleashed the storm around Valeant Pharmaceuticals International Inc., is quick to swat away all the good things billionaire William Ackman has to say about stricken drug company.
Ackman, whose Pershing Square Capital Management is one of Valeant’s biggest shareholders, hadn’t even finished his highly anticipated defense of the company Friday before Left fired another shot -- and sent Valeant’s share price tumbling anew.